[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100496585":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":27,"locations":33,"responsibleParty":50,"collaborators":11,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":11,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":11,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":76,"overallStatus":36,"whyStopped":11,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"University of Southern California","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Zolpidem","EXPERIMENTAL",null,[13],"Drug: Zolpidem Tartrate 10 mg",{"label":15,"type":16,"description":11,"interventionNames":17},"Placebo","PLACEBO_COMPARATOR",[18],"Drug: Placebo",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"DRUG","Zolpidem Tartrate 10 mg","two days preoperatively and five days postoperatively",[9],{"type":21,"name":15,"description":23,"armGroupLabels":26,"otherNames":11},[15],[28],{"name":29,"role":30,"phone":31,"phoneExt":11,"email":32},"Pui Yan, MS","CONTACT","323-442-6984","puiyan@med.usc.edu",[34],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Keck Medical Center of USC","RECRUITING","Los Angeles","California","90033","United States","US",{"type":43,"coordinates":44},"Point",[45,46],-118.24368,34.05223,{"lat":46,"lon":45},[49],{"name":29,"role":30,"phone":31,"phoneExt":11,"email":32},{"type":51,"investigatorFullName":52,"investigatorTitle":53,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Raymond Hah","Assistant Professor of Clinical Orthopaedic Surgery","100496585","phase-4-the-effect-of-zolpidem-on-outcomes-following-lumbar-spine-fusion-100496585",false,"NCT05746143","The Effect of Zolpidem on Outcomes Following Lumbar Spine Fusion","The Effect of Zolpidem on Outcomes Following Lumbar Spine Fusion: A Randomized Control Trial","Inclusion Criteria:\n\n* degenerative lumbar disease\n* age of 18-75\n* undergoing open primary one- to three-level lumbar fusion\n\nExclusion Criteria:\n\n* currently use a sleep aid nightly\n* diagnosed with insomnia or sleep apnea\n* history of delirium with opiates or zolpidem\n* allergic to opiates or zolpidem\n* had previous lumbar spine surgery\n* undergoing minimally invasive lumbar fusion,\n* undergoing lumbar fusion for fracture, infection, tumor, or an inflammatory spondyloarthropathy","ALL","18 Years","75 Years",{"count":65,"type":66},140,"ESTIMATED","INTERVENTIONAL",[69],"PHASE4","The purpose of this study is to evaluate if peri-operative zolpidem for posterior lumbar spinal fusion improves patient reported outcomes following surgery.",[72,73,74,75],"Spine Fusion","Lumbar Spine Degeneration","Pain, Postoperative","Lumbar Spine Spondylosis",[77,9,78],"Lumbar Spine Fusion","Postoperative Outcomes","2026-04-29",{"date":81,"type":82},"2026-05-01","ACTUAL",{"date":84,"type":82},"2022-02-01",{"date":86,"type":66},"2030-12-31",{"name":5,"class":6},1]